ASCO26: BMS and J&J debut shining multiple myeloma data

Both BMS and J&J touted positive data for their multiple myeloma drugs at ASCO 2026. Both BMS and J&J touted positive data for their multiple myeloma drugs at ASCO 2026. These trials show meaningful progress in RRMM. Credit: Nemes Laszlo / Shutterstock.com Several companies have presented compelling data from multiple myeloma studies at the 2026 American Society of Clinical Oncology (ASCO) meeting. Data was announced by both Bristol Myers Squibb (BMS) and Johnson and Johnson (J&J), as well as an investigator-led study looking into the use of certain myeloma therapies in the outpatient setting. LOA and PTSR Model AZD-0466…

Source: Clinical Trials Arena